CHCI vs. BCRX
CHCI (Comstock Holding Companies, Inc.) and BCRX (BioCryst Pharmaceuticals, Inc.) are both stocks. CHCI operates in Real Estate - Diversified (Real Estate), while BCRX operates in Biotechnology (Healthcare). Over the past 10 years, CHCI returned 23.55%/yr vs 12.40%/yr for BCRX. At a 0.08 correlation, their price movements are largely independent.
Performance
CHCI vs. BCRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CHCI achieves a 29.09% return, which is significantly higher than BCRX's 17.18% return. Over the past 10 years, CHCI has outperformed BCRX with an annualized return of 23.55%, while BCRX has yielded a comparatively lower 12.40% annualized return.
CHCI
- 1D
- 0.00%
- 1M
- 0.94%
- YTD
- 29.09%
- 6M
- 35.38%
- 1Y
- 48.08%
- 3Y*
- 58.60%
- 5Y*
- 20.03%
- 10Y*
- 23.55%
BCRX
- 1D
- 1.67%
- 1M
- 10.25%
- YTD
- 17.18%
- 6M
- 20.11%
- 1Y
- -9.50%
- 3Y*
- 9.25%
- 5Y*
- -11.66%
- 10Y*
- 12.40%
CHCI vs. BCRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CHCI Comstock Holding Companies, Inc. | 29.09% | 43.81% | 82.32% | 4.28% | -12.37% | 53.00% | 62.02% | 16.46% | -1.18% | -5.56% |
BCRX BioCryst Pharmaceuticals, Inc. | 17.18% | 3.72% | 25.54% | -47.82% | -17.11% | 85.91% | 115.94% | -57.25% | 64.36% | -22.43% |
Correlation
The correlation between CHCI and BCRX is 0.10, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.10 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.04 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.06 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.04 |
Correlation (All Time) Calculated using the full available price history since Dec 14, 2004 | 0.08 |
Fundamentals
CHCI:
$157.40M
BCRX:
$2.21B
CHCI:
$1.66
BCRX:
-$2.03
CHCI:
2.32
BCRX:
2.33
CHCI:
$67.67M
BCRX:
$885.72M
CHCI:
$15.13M
BCRX:
$167.34M
CHCI:
$13.31M
BCRX:
-$374.88M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CHCI vs. BCRX — Risk / Return Rank
CHCI
BCRX
CHCI vs. BCRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Comstock Holding Companies, Inc. (CHCI) and BioCryst Pharmaceuticals, Inc. (BCRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CHCI | BCRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.95 | ||
| Sortino ratioReturn per unit of downside risk | +1.44 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.00 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 1.09 | -0.26 | +1.35 |
| Martin ratioReturn relative to average drawdown | 2.05 | -0.46 | +2.51 |
Loading charts...
Drawdowns
CHCI vs. BCRX - Drawdown Comparison
The maximum CHCI drawdown since its inception was -99.80%, roughly equal to the maximum BCRX drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for CHCI and BCRX.
Loading charts...
Drawdown Indicators
| CHCI | BCRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.80% | -97.74% | -2.06% |
Max Drawdown (1Y)Largest decline over 1 year | -44.23% | -37.16% | -7.07% |
Max Drawdown (3Y)Largest decline over 3 years | -47.93% | -47.85% | -0.08% |
Max Drawdown (5Y)Largest decline over 5 years | -47.93% | -79.10% | +31.17% |
Max Drawdown (10Y)Largest decline over 10 years | -75.34% | -83.69% | +8.35% |
Current DrawdownCurrent decline from peak | -92.78% | -72.41% | -20.37% |
Average DrawdownAverage peak-to-trough decline | -92.09% | -69.64% | -22.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.50% | 21.92% | +1.58% |
Volatility
CHCI vs. BCRX - Volatility Comparison
Comstock Holding Companies, Inc. (CHCI) has a higher volatility of 21.33% compared to BioCryst Pharmaceuticals, Inc. (BCRX) at 12.92%. This indicates that CHCI's price experiences larger fluctuations and is considered to be riskier than BCRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CHCI | BCRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.33% | 12.92% | +8.41% |
Volatility (6M)Calculated over the trailing 6-month period | 42.88% | 34.53% | +8.35% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.61% | 44.94% | +20.67% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 61.34% | 62.06% | -0.72% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 93.23% | 72.63% | +20.60% |
Dividends
CHCI vs. BCRX - Dividend Comparison
Neither CHCI nor BCRX has paid dividends to shareholders.
Financials
CHCI vs. BCRX - Financials Comparison
This section allows you to compare key financial metrics between Comstock Holding Companies, Inc. and BioCryst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CHCI and BCRX have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CHCI has higher volatility (21.33%) compared to BCRX (12.92%). In terms of maximum drawdown, CHCI dropped -99.80% vs BCRX's -97.74%.
CHCI currently has the higher Sharpe Ratio (0.74 vs -0.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CHCI and BCRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer